Differences of Lymphocyte Dna Methylation Profiles Between People with and Without Metabolic Syndrome

Parco M. Siu,Xiao M. Pei,Nancy B. Tsui,Shea P. Yip,Lawrence W. Chan,Cesar S. Wong,Benjamin Y. Yung

DOI: https://doi.org/10.1249/01.mss.0000477667.77240.47

2015-01-01

Abstract:Metabolic syndrome (MetS) increases the risk of type 2 diabetes and cancer. DNA methylation might be a key epigenetic mechanism that regulates the expression of genes responsible for the development of metabolic disease and cancer. PURPOSE: We investigated the genome-wide profile of DNA methylation in lymphocytes extracted from women with and without MetS (n = 9 in each group). METHODS: DNA methylation analysis was performed using the platform of Infinium HumanMethylation450 BeadChip. RESULTS: Total of 22,429 CpG sites showed changes at DNA methylation level in MetS subjects at an unadjusted two-side p value threshold of 0.05 (4.6%). 11,970 CpG sites showed increased methylation whereas 10,459 CpG sites showed reduced methylation. Specific CpG sites of the RUFY1, ZC3H12D, GPN2, KCTD11, CCDC28A promoters were the most significantly regulated (FDR < 0.5) with hypomethylation in MetS subjects. Metacore analysis (in putting differentially methylated genes at FDR threshold of 0.75 between MetS and healthy subjects) identified the molecular pathway most likely to be involved in the Transcription Receptor-mediated HIF regulation (p = 1.317 × 10−3), Hypoxia-induced EMT in cancer and fibrosis (p = 1.265 × 10−2), Transport Rab-9 regulation pathway (p = 1.405 × 10−2), DNA damage NHEJ mechanisms of DSBs repair (p = 2.653 × 10−2), Development of EGFR signaling via PIP3 (p = 3.204 × 10−2). To better understand the mechanisms of the initiation of diabetes and cancer in MetS subjects, DNA methylation levels of CpG sites located in promoters of the type 2 diabetes-related and tumor suppressor genes were further analyzed. β values of the CpG sites with mean methylation differences of > 2% and p < 0.05 in promoter region of diabetes-related genes including ADIPOR1, TNFRSF1B, NFKB1A, SOCS3, PYCARD, and tumor suppressor genes including PTEN, BRCA1, and STK11. Their absolute methylation levels will be validated by pyrosequencing with a larger sample size. CONCLUSION: MetS affects the genome-wide DNA methylation in human lymphocytes, potentially regulating specific gene expressions resulting in novel insights to understand the relationships among metabolic syndrome, type 2 diabetes and cancer.